Edwards Syndrome (Trisomy 18) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Edwards Syndrome (Trisomy 18) Market Outlook

Thelansis’s “Edwards Syndrome (Trisomy 18) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Edwards Syndrome (Trisomy 18) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Edwards Syndrome (Trisomy 18) Overview

Edwards syndrome (Trisomy 18) is an autosomal chromosomal disorder characterized by an additional copy of chromosome 18. This condition is classified as one of the autosomal trisomy syndromes, with trisomy 21 being the most common. The occurrence of Edwards syndrome is primarily attributed to the presence of an extra copy of chromosome 18q. There are three distinct types of Edwards syndrome: complete trisomy 18, which accounts for approximately 94% of cases, mosaic trisomy 18, which constitutes less than 5%; and partial trisomy 18, which is responsible for 2% of cases. The risk of recurrence for complete trisomy 18 in subsequent pregnancies is estimated to be between 0.5% and 1%. The characteristic features of Edwards syndrome are believed to be associated with three copies of specific regions on the long arm of chromosome 18, specifically 18q12.1 to 18q21.2 and 18q22.3 to 18qter. Severe intellectual disability observed in individuals with Edwards syndrome may be linked to the trisomy of the 18q12.1 to 18q21.2 region. Notably, trisomy of the short arm of chromosome 18 (18p) does not seem to contribute significantly to the significant features of Edwards syndrome. Currently, there is no definitive treatment available for Edwards syndrome. Approximately 40% of affected fetuses do not survive labor, and about one-third of the surviving fetuses are born prematurely. The median survival time for individuals with Edwards syndrome ranges from 3 days to 14.5 days. The survival rates are approximately 60% to 75% at the end of the first week, 20% to 40% at the end of the first month, and 10% at the end of the first year. Only 5% to 10% of individuals with Edwards syndrome survive beyond their first year.

• The incidence of Edwards syndrome is 0.3 per 1000 live births, and females are affected more often than males (3:1).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: